Price T Rowe Associates Inc Arcellx, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,900,611 shares of ACLX stock, worth $147 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,900,611
Previous 1,630,690
16.55%
Holding current value
$147 Million
Previous $90 Million
76.36%
% of portfolio
0.02%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding ACLX
# of Institutions
204Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$310 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$302 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$291 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$273 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$191 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.4B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...